CEO: Ascent's drug candidate seen as rival to Genzyme's Mozobil

09/17/2009 | Xconomy

Ascent Therapeutics says trials using animal models show its drug candidate for certain blood cancers to be as effective as Genzyme's Mozobil in stimulating stem cell movement out of the bone marrow. The drug is a potential treatment for patients with blood cancers, including non-Hodgkin's lymphoma and multiple myeloma, who require transplants of blood-forming stem cells. The drug also could be developed for use in freeing cancer cells from the bone marrow into the bloodstream to make it easier for chemotherapy drugs to eliminate them, Ascent CEO Rick Jones said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN